#VisualAbstract: Adjuvant nivolumab may be promising for treatment of completely resected Merkel cell carcinoma
1. Disease-free survival at 24 months was 84% in the nivolumab group compared to 73% in the observation group. 2. ...
1. Disease-free survival at 24 months was 84% in the nivolumab group compared to 73% in the observation group. 2. ...
1. Disease-free survival at 24 months was 84% in the nivolumab group compared to 73% in the observation group. 2. ...
1. Objective response rate was not significantly different in patients treated with stereotactic body radiotherapy compared to those without. 2. ...
Click to read this study in JAMA Dermatology.
Click to read this study in JAMA Dermatology.
Click to read the study in the Journal of the American Academy of Dermatology.
Click to read the study in JAMA Dermatology.
Click to read the study in the Journal of the American Academy of Dermatology.
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.